Answers are grounded in this paper and cite their sources.
INTRODUCTION: Gemcitabine is a pyrimidine nucleoside analog that becomes triphosphorylated and competitively inhibits cytidine incorporation into DNA strands. Diphosphorylated gemcitabine irreversibly inhibits ribonucleotide reductase thereby preventing deoxyribonucleotide synthesis. Functioning as a potent chemotherapeutic, gemcitabine decreases neoplastic cell proliferation and induces apoptosis which accounts for its effectiveness in the clinical treatment of several leukemia and carcinoma cell types. A brief plasma half-life due to rapid deamination, chemotherapeutic-resistance and sequelae restrict gemcitabine utility in clinical oncology. Selective "targeted" gemcitabine delivery represents a molecular strategy for prolonging its plasma half-life and minimizing innocent tissue/organ exposure. METHODS: ]. RESULTS: ] or gemcitabine alone. CONCLUSION: ] compared to benzimidazole tubulin/microtubule inhibitors.
No takes yet. Share an insight, caveat, or question.
Coyne et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: